Morgan Stanley Connect Biopharma Holdings LTD Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.28 - $2.2 $4,567 - $7,849	3,568 New	3,568 $5,000
Q1 2023 May 15, 2023	SELL	$0.82 - $1.32 $293 - $472	-358 Reduced 99.72%	1 $0
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.31 $4,948 - $10,128	-7,732 Reduced 95.56%	359 $0
Q3 2022 Nov 14, 2022	SELL	$0.8 - $1.65 $51 - $105	-64 Reduced 0.78%	8,091 $10,000
Q2 2022 Oct 27, 2022	SELL	$0.56 - $3.25 $381 - $2,213	-681 Reduced 7.71%	8,155 $7,000
Q2 2022 Aug 15, 2022	SELL	$0.56 - $3.25 $381 - $2,213	-681 Reduced 7.71%	8,155 $7,000
Q1 2022 Oct 27, 2022	BUY	$2.46 - $5.92 $1,675 - $4,031	681 Added 8.35%	8,836 $27,000
Q1 2022 May 13, 2022	BUY	$2.46 - $5.92 $8,701 - $20,939	3,537 Added 66.75%	8,836 $27,000
Q4 2021 Feb 14, 2022	BUY	$4.26 - $23.33 $22,573 - $123,625	5,299 New	5,299 $27,000

3.05M

Ticker CNTB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,015,800
Market Cap $53.9M
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.